




Contents lists available at ScienceDirect

NeuroImage

journal homepage: www.elsevier.com/locate/ynimg

Long-term reproducibility of GABA magnetic resonance spectroscopy

Q1 Jamie Near^{a,b,*}, Yi-Ching Lynn Ho^c, Kristian Sandberg^{d,e}, Chathura Kumaragamage^b, Jakob Udby Blicher^{c,f}

^a Douglas Mental Health University Institute and Department of Psychiatry, McGill University, 6875 LaSalle Blvd, Montreal H4H 1R3, Canada

^b Department of Biomedical Engineering, McGill University, Room 316, Duff Medical Building, 3775 Rue University, Montreal H3A 2B4, Canada

^c Center for Functionally Integrative Neuroscience (CFIN), Aarhus University, Nørrebrogade 44, Building 10G, 5th Floor, 8000 Aarhus C, Denmark

^d Cognitive Neurosciences Research Unit (CNRU), Hammel Neurorehabilitation Centre and University Research Clinic, Aarhus University, Nørrebrogade 44, Building 10G, 8000 Aarhus C, Denmark

^e UCL Institute of Cognitive Neurosciences, University College London, Alexandra House, 17 Queen Square, London WC1N 3AR, UK

^f Hammel Neurorehabilitation and Research Centre, Aarhus University Hospital, Voldbyvej 15, 8450 Hammel, Denmark

ARTICLE INFO

Article history:

Accepted 20 May 2014

Available online xxx

Keywords:

Magnetic resonance spectroscopy (MRS)

Gamma aminobutyric acid (GABA)

Long-term reproducibility

Brain

Neurotransmitter

ABSTRACT

Recent findings suggest that cortical gamma aminobutyric acid (GABA) levels may provide a surrogate marker for a number of psychiatric and neurological conditions, as well as behavioural traits. However, the natural variability of GABA levels in the human brain over long periods of time (>8 days) has not yet been studied. The purpose of this work was to investigate the long-term variability of GABA concentrations in the human occipital cortex. Nineteen healthy male participants were recruited and underwent two sessions of magnetic resonance spectroscopy (MRS) to determine occipital GABA levels with an average between-session interval of 7 months. We assessed between-session variability, as well as the correlation between session 1 and session 2 GABA measurements. The mean coefficient of variation between sessions was 4.3% (bootstrap 95% confidence interval: 2.5, 6.4), which is comparable to reported GABA variability measurements over much shorter time intervals (<8 days). A significant positive correlation was observed between session 1 and session 2 GABA measurements ($r = 0.53$, $p = 0.014$), and the intra-class correlation coefficient was calculated to be 0.52 which was also statistically significant ($p = 0.012$). These findings establish experimentally that GABA concentrations in the occipital cortex as measured by MRS are relatively stable over periods as long as 7 months. The findings have significant implications for the internal validity of longitudinal studies of GABA levels in the human brain, and they lend foundational support to studies relating GABA levels to behavioural traits in healthy individuals.

© 2014 Published by Elsevier Inc.

Introduction

Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the brain and plays an important role in regulating neuronal activity (McCormick, 1989). Abnormal GABA levels are implicated in various neurological and psychiatric conditions including stroke (Lei et al., 2009), epilepsy (Petroff et al., 1996), motor neuron disease (Foerster et al., 2012), ADHD (Edden et al., 2012a), schizophrenia (Kegeles et al., 2012; Rowland et al., 2013) and depression (Bhagwagar et al., 2007). GABA levels are also correlated with functional measures such as cerebral blood flow and the blood oxygen level dependent functional magnetic resonance imaging contrast (Donahue et al., 2010; Muthukumaraswamy et al., 2009). A growing body of new evidence suggests that in addition to its involvement in diseases and functional metrics, GABA also acts as a surrogate marker for a number of behavioural measures such as rash impulsivity (Boy et al.,

2011), subconscious motor control (Boy et al., 2010), motor decision speed (Sumner et al., 2010), and tendency for cognitive failures (Sandberg et al., 2013) among others (Jocham et al., 2012). As the full relationship between GABA levels and behaviour continues to be uncovered, questions arise regarding the long-term stability of GABA levels; whether or not GABA levels remain stable over long periods of time will have important implications in the types of behaviours (trait vs. state) that GABA levels can be hypothesized to predict.

Measures of brain GABA levels are most commonly obtained using magnetic resonance spectroscopy (MRS), which currently provides the only non-invasive means to detect GABA levels in vivo. Using MRS, the short-term variability of cerebral GABA levels has been well characterized. Specifically, when GABA measurements are repeated in separate sessions up to 8 days apart in healthy male participants, the coefficient of variation (CV) ranges from 3.5 to 21% (Evans et al., 2010; Stephenson et al., 2011; Wijtenburg et al., 2013), which falls roughly within the same range as the within-session CV of the measurement technique (7–13%) (Bogner et al., 2010; Near et al., 2013; O’Gorman et al., 2011). Therefore over time intervals of 8 days or less, individual GABA levels are believed to be stable, and most of the variability observed in repeated GABA measurements on these time intervals can likely be attributed to measurement error.

* Corresponding author at: Room GH-2113, CIC Pavilion, Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal H4H 1R3, Canada. Fax: +1 514 888 4487.

E-mail address: jamie.near@mcgill.ca (J. Near).

In the longer-term (>8 days), one study found that GABA levels in plasma are stable over a four year interval in subjects with depression (Petty et al., 1995), however investigations of the long-term stability of GABA levels in the brain have yet to be performed. The purpose of this study was, therefore, to investigate the long-term variability of brain GABA levels using repeated MRS measurements in occipital cortex. Nineteen participants were each scanned twice with a between-scan interval of approximately seven months, and we determined the average CV of the repeated GABA measurements, as well as the correlation between repeated measurements. Furthermore, we investigated the effect of voxel repositioning error on between-session variability.

Materials and methods

In vivo MRS experiments

19 healthy male subjects (mean age 24 ± 3 years) were recruited to participate in this study. To avoid the potential confound of cyclical variation in GABA levels with the menstrual cycle (Epperson et al., 2006; Harada et al., 2011) only male participants were used. All subjects provided informed, written consent and experiments were approved by the local ethics committee, De Videnskabsetiske Komitéer for Region Midtjylland. All participants were scanned twice, with an average between-scan interval of 229 ± 42 days (~7.5 months), on a 3 Tesla Magnetom Trio system (Siemens, Erlangen, Germany) with a body coil transmitter and a 32-channel head receiver array coil. In all scans, high resolution T1-weighted MPRAGE structural images were acquired (TR/TE = 2420/3.7 ms, 1 mm isotropic resolution, 5.5 minute scan) and used to guide placement of a $3 \times 3 \times 3$ cm³ MRS voxel in occipital cortex. GABA edited MRS was performed using MEGA-PRESS (Mescher et al., 1998) with the following scan parameters: TR/TE = 2500/68 ms, 2048 points, 2000 Hz spectral width, and 192 averages for a total scan time of 8 min. Dual banded Gaussian shaped editing pulses with a 20 ms duration were applied with a water suppression band at 4.7 ppm and an editing band that alternated between 1.9 ppm and 7.5 ppm in even (edit-on) and odd (edit-off) scans, respectively.

MRS data processing and analysis

Data were processed using semi-automated in-house MATLAB processing routines as described previously (Near et al., 2013). Specifically, a weighted array coil recombination was performed, followed by an automated procedure to remove averages corrupted by motion. Time-domain spectral registration of averages (Near et al., 2014) was then performed separately on both the edit-on and edit-off scans to correct frequency and phase drift errors, prior to summation. Finally, the averaged edit-on and edit-off spectra were manually aligned by frequency and phase adjustment to minimize the residual choline difference signal, and the edit-on and edit-off scans were then subtracted (edit-on – edit-off) to produce a difference spectrum, and combined (edit-on + edit off) to produce a sum spectrum. Fully processed difference and sum spectra were analysed by peak fitting using jMRUI (Naressi et al., 2001) as described previously (Near et al., 2011). GABA concentrations were referenced to total creatine (creatine plus phosphocreatine, Cr), which was measured from the 3.0 ppm creatine resonance in the sum spectrum, and all metabolite concentrations were corrected for T₂ relaxation during the echo time by assuming T₂ values of 88 and 116 ms for GABA and Cr, respectively (Edden et al., 2012b). GABA concentrations were also corrected for the editing efficiency of the MEGA-PRESS sequence, which was assumed to be 41% (Near et al., 2011).

Statistical analyses

As a measure of the variability of GABA levels between sessions, the coefficient of variation was determined for each subject. To test the bivariate relationship between session 1 and session 2 GABA

measurements, the Pearson product-moment correlation coefficient (r) between sessions was calculated. Finally, as a measure of the likeness of repeated GABA measurements to each other, the intra-class correlation coefficient for absolute agreement of single measures (as opposed to average measures) was calculated using a two-way mixed effects model, ICC(3,1) (McGraw and Wong, 1996).

To assess the effect of voxel repositioning errors on the between-session reproducibility of GABA measurements, a voxel mask was first generated for each MRS acquisition and overlaid with the high-resolution anatomical image from the corresponding session. Using SPM8 (<http://www.fil.ion.ucl.ac.uk/spm/software/spm8/>), image coregistration was then performed to align each subject's session 2 anatomical scan with their session 1 anatomical scan, and the same linear transformation was applied to each subject's session 2 voxel mask to enable determination of the between-session fraction of voxel overlap (FO, common voxel volume divided by the volume of a single voxel). Finally, the bivariate correlation between FO and log(CV) was tested.

Data from two of the nineteen participants were excluded from the final analysis; the first due to severe unsuppressed water signal contamination in one MRS session, and the second due to a large voxel repositioning error (FO = 0.59) which was determined to be an outlier. Thus, the remaining seventeen participants were included in final analyses. For GABA measurements at sessions 1 and 2 as well as FO, Shapiro–Wilk tests and histogram inspection did not refute the assumption of normality ($W > 0.92$, $p > 0.15$ for all variables), and Cook–Weisberg tests did not refute the assumption of homoscedasticity ($\chi^2(1) < 1.50$, $p > 0.12$ for all variables). For this reason, the relationship between session 1 and session 2 GABA levels was tested using the parametric Pearson product-moment correlation (r). However, for CV measurements, Shapiro–Wilk test and histogram did refute the assumption of normality ($W < 0.84$, $p < 0.01$). Therefore, confidence intervals on mean CV values were obtained via bootstrap resampling. Specifically, data were resampled 10,000 times (with replacement) and the 95% confidence interval was determined to be the middle 95% of the resampled means. Furthermore, for correlational analyses, CV values were log transformed. Then, for log(CV) values, Shapiro–Wilk tests did not refute the assumption of normality ($W > 0.92$, $p > 0.19$) and Cook–Weisberg tests did not refute the assumption of homoscedasticity ($\chi^2 < 2.4$, $p > 0.12$). All relationships were linear (see Results).

To enable evaluation of the null hypothesis that the measured long term CVs for GABA were not significantly greater than previously reported CVs for GABA over shorter time intervals (<8 days), the distribution of likelihood ratios for log(CV) was calculated based on the sample characteristics (mean and standard error of log(CV)), and the assumption of approximate normality. From this distribution, the credibility interval, the interval corresponding to the 1/32nd amplitudes of the likelihood ratio distribution, was calculated.

The relationship between FO and log(CV) was tested in the following two ways. Firstly, the parametric Pearson product-moment correlation (r) was calculated. Secondly, a distribution of the posterior probability of the strength of the correlation (r) between FO and log(CV) was generated using a Markov Chain Monte Carlo (MCMC) simulation, as implemented using R (The R Project for Statistical Computing, www.r-project.org) and JAGS (Just Another Gibbs Sampler, mcmc-jags.sourceforge.net). MCMC simulation was performed using a bivariate normal distribution model with parameters r , μ_{FO} , $\mu_{\log(CV)}$, σ_{FO} , and $\sigma_{\log(CV)}$, where μ and σ are the estimated population mean and standard deviation, respectively. The following prior probability distributions were specified for each of the five model parameters:

$$\begin{aligned} r &\sim \text{unif}[-1, 0] \\ \mu_{FO} &\sim \text{unif}[0.5, 1] \\ \sigma_{FO} &\sim \text{unif}[0, 0.5] \\ \mu_{\log(CV)} &\sim \text{unif}[-2.3, 3] \\ \sigma_{\log(CV)} &\sim \text{unif}[0, 3] \end{aligned}$$

200 where $\text{unif}[A,B]$ represents a uniform distribution from A to B. Notably,
 201 the prior probability distribution of r included only values less than or
 202 equal to zero, since a positive correlation between FO and $\log(\text{CV})$ cor-
 203 responds to the impossible scenario that poorer voxel repositioning
 204 leads to lower CV's.


205 Finally, GABA levels in this study were presented as a ratio with total
 206 creatine because at least one previous study showed that creatine
 207 referencing results in optimal reproducibility (Bogner et al., 2010).
 208 Nonetheless, to rule out the possibility that variability of GABA concentra-
 209 tions could be masked by covariability with creatine, GABA/NAA
 210 ratios and NAA/Cr ratios were also determined by measuring the residual
 211 NAA peak in difference spectra, and the CV for long-term repeated mea-
 212 sures of each of these quantities was also calculated.

213 Results

214 Fig. 1 shows pairs of occipital GABA MRS difference spectra, obtained
 215 with an average between-scan interval of ~7 months, from all 17
 216 included participants. The edited GABA resonance appears at 3 ppm.
 217 For display purposes, the amplitude of each spectrum in Fig. 1 was
 218 scaled in proportion the measured amplitude of the creatine peak in
 219 the corresponding sum spectrum. Very good visual correspondence
 220 was observed between the repeated measurements.

221 Fig. 2 shows the measured GABA/Cr concentrations for both sessions
 222 in each subject. Across the 17 subjects, the between-session CV ranged
 223 from 0.2% to 12.3%, with a mean of 4.3% and a bootstrapped 95% confi-
 224 dence interval (CI) of [2.5, 6.4]%. The mean CV is similar in magnitude
 225 to previously reported measurements of GABA variability over much
 226 shorter time intervals (<8 days). The ratios of GABA/NAA and NAA/Cr
 227 also displayed similar reproducibility between sessions, with mean CV
 228 values of 4.9% and 5.1%, respectively, and bootstrapped 95% CIs of [3.5,
 229 6.4]% and [3.6, 6.7]%, respectively.

230 Based on the sample characteristics and the assumption of an approxi-
 231 mately normal distribution on $\log(\text{CV})$, Fig. 3 shows the calculated
 232 distribution of likelihood ratios for $\log(\text{CV})$. The credibility interval on




233 Fig. 2. The session 1 and session 2 occipital GABA/Cr measurements in 17 healthy partici-
 234 pants. The average coefficient of variation between sessions was $4.3 \pm 4.2\%$ across all
 235 subjects.

236 $\log(\text{CV})$, or the interval corresponding to the 1/32nd amplitudes of the
 237 likelihood ratio distribution is $[-0.09, 1.75]$, which, by inverse log
 238 transformation, corresponds to a credibility interval on CV of [0.9, 5.8]%.
 239

240 The correlation between session 1 and session 2 GABA measure-
 241 ments was $r(15) = 0.53$, $p = 0.014$ (Fig. 4), indicating a significant posi-
 242 tive correlation, and the intra-class correlation coefficient was $r = 0.52$,
 243 $p = 0.012$, indicating statistically significant absolute agreement
 244 between GABA levels at seven month intervals.

245 Fig. 5a shows an example of voxel positions for the two subjects who
 246 had the lowest (76%, left) and highest (93%, right) FO values, respective-
 247 ly. The average FO across subjects was $84.5\% \pm 5.8\%$. No significant
 248 correlation was observed between $\log(\text{CV})$ and FO ($\rho(15) = 0.05$,
 249 $p = 0.84$, Fig. 5b). Furthermore, Fig. 5c shows the estimated Bayesian
 250 posterior distribution of r obtained by MCMC simulation. Based
 251 on this distribution, the maximum-likelihood estimate (MLE) of r



252 Fig. 1. Pairs of occipital GABA MRS difference spectra (TR/TE = 2500/68 ms, 192 averages, 8 minute scan), obtained with an average between-scan interval of ~7 months, from 17 healthy male participants. The edited GABA resonance appears at 3 ppm. For display purposes, the amplitude of each spectrum in Fig. 1 was scaled in proportion the measured amplitude of the creatine peak in the corresponding sum spectrum. No filtering was applied. Very good visual correspondence was observed between the repeated measurements.




Fig. 3. Distribution of likelihood ratios for $\log(\text{CV})$, based on the sample characteristics and assuming a normal distribution. The credibility interval, or the 1/32nd amplitudes of the distribution, is $[-0.09, 1.75]$, which corresponds to an interval on CV of $[0.9, 5.8\%]$ following inverse log transformation.

(corresponding to the maximum amplitude of the posterior distribution) is -0.01 , and the Bayes estimate (BE) of r (corresponding to the mean value of the distribution) is -0.19 .

251 Discussion

252 Taken together, the results of this study establish experimentally
 253 that GABA concentrations in the occipital cortex as measured by MRS
 254 are relatively stable over periods as long as 7 months. In repeated
 255 measurements using edited MRS at 3 T with a between-scan interval of
 256 7 months, the mean observed variability of GABA levels was 4.3%,
 257 which is comparable to those reported over short time intervals
 258 (<8 days) using similar methodology (Bogner et al., 2010; Near et al.,
 259 2013; O’Gorman et al., 2011; Wijtenburg et al., 2013). The similarly
 260 low variability in the ratios of GABA/NAA (4.9%) and NAA/Cr (5.1%) ef-
 261 fectively rules out the possibility that larger between-session variability
 262 in GABA levels was masked by correlated variability in Cr levels. Based
 263 on the likelihood distribution of $\log(\text{CV})$, the upper estimate of the vari-
 264 ability of GABA levels over long time intervals was 5.8%, which was still
 265 not greater than a majority of previously published short term GABA
 266 variability estimates, suggesting that the dominant source of variability
 267 in repeated GABA measurements, even over intervals as long as seven
 268 months, is likely due to measurement error.




Fig. 4. Scatter plot of session 1 versus session 2 GABA measurements. A significant positive correlation ($r(15) = 0.53$, $p = 0.014$) and a significant intraclass correlation ($r = 0.52$, $p = 0.012$) between the two sessions was observed.






Fig. 5. Effect of between-session voxel repositioning error on between-session GABA measurement variability. a) Session 1 (green) and session 2 (red) voxel positions are shown for the subjects with the poorest voxel repositioning (76% voxel overlap, left) and the best voxel repositioning (93% voxel overlap, right). The average between-session voxel overlap was $84.5\% \pm 5.8\%$. b) Scatter plot of $\log(\text{CV})$ versus between-session voxel overlap (FO). Voxel repositioning errors did not explain differences in GABA measurement reproducibility between individuals. c) Posterior probability distribution of the correlation, r , between $\log(\text{CV})$ and FO, generated using a Markov Chain Monte Carlo simulation, and with a flat, one-sided prior on r ($-1 \leq r \leq 0$). The maximum likelihood estimate of r is -0.01 and the Bayes estimate is -0.19 , suggesting a weak inverse relationship between $\log(\text{CV})$ and FO.

The observed intra-class correlation coefficient of 0.52 was statistically significant, meaning that repeated measurements acquired seven months apart strongly resemble each other (with absolute agreement) when between-subject variations are taken into account. Based on the conventions outlined in (Cicchetti and Sparrow, 1981), an ICC between 0.40 and 0.59 is considered ‘fair’. It is important to note, however, that even in the hypothetical case that GABA levels are identical between

276 sessions, the ICC would still never approach unity due to experimental
277 test–retest variability, which, as mentioned above, has been shown in
278 previous short-term reproducibility studies to result in CVs similar to
279 those obtained in this study.

280 The observed variation in GABA levels between sessions was not
281 explained by errors in voxel positioning. However, based on the poste-
282 rior probability distribution of the correlation, r , between $\log(\text{CV})$ and
283 FO, and assuming a flat, one-sided prior distribution on r ($-1 \leq r$
284 ≤ 0), a weak inverse correlation between $\log(\text{CV})$ and FO is predicted.
285 This result agrees with what one might have expected intuitively if
286 we assume that spatial variation of GABA levels in the occipital cortex
287 is small. The above result is an important one, as it suggests that GABA
288 levels are only weakly affected by voxel positioning in the occipital
289 cortex, and therefore perfect voxel repositioning is not absolutely critical
290 in longitudinal GABA studies in the occipital cortex.

291 The finding of relatively stable GABA concentrations over the long
292 term suggests that GABA levels are a reflection of trait, rather than
293 state. This finding provides foundational support for the growing body
294 of research in which GABA levels are related to behavioural traits (Boy
295 et al., 2010; Boy et al., 2011; Jocham et al., 2012; Sandberg et al., 2013;
296 Sumner et al., 2010). Furthermore, the finding of stable GABA levels
297 over long periods of time in healthy subjects suggests that GABA is an
298 appropriate target for placebo-controlled longitudinal studies involving
299 pharmacological agents, neuromodulative therapies (rTMS, etc.) or
300 induction of plasticity changes, since longitudinal GABA measurements
301 are not likely to be confounded by normal long-term (on the order of
302 7 months) GABA fluctuations. Over time intervals much longer than
303 7 months, GABA levels in adults are expected to decline slowly, based
304 on the results of a cross-sectional study showing reduced GABA levels
305 in older participants (Gao et al., 2013).

306 Due to the use of single voxel MRS in this study, the finding of long-
307 term stability of GABA levels is specific to the occipital cortex. Future
308 studies are required to assess the long-term stability of GABA levels in
309 other cortical regions. It should be noted that the occipital cortex pro-
310 vides relatively favourable MRS data quality compared with some previ-
311 ously studied regions such as the anterior cingulate (Stephenson et al.,
312 2011; Wijtenburg et al., 2013) or the dorsolateral prefrontal cortex
313 (O’Gorman et al., 2011; Wijtenburg et al., 2013). Therefore, poorer mea-
314 surement reproducibility might be expected in other brain regions due
315 to increased measurement error.

316 It was noticed that the four subjects with the largest changes in
317 GABA levels (subjects 1, 3, 6 and 13) all exhibited positive changes in
318 GABA levels over the seven month interval, with CVs of 10.3, 11.4,
319 10.5 and 12.3% respectively. This fact resulted in a slight deviation
320 from the diagonal in the slope of the relationship between session 1
321 and session 2 GABA levels, and we cannot rule out the possibility that
322 some unexplained factor caused real increases in GABA levels in these
323 four subjects. However, we judge that this is most likely a chance occur-
324 rence, and we also note that even the magnitudes of these four largest
325 GABA changes were similar or smaller than what some authors have re-
326 ported as the average CV of GABA levels over short time intervals
327 (<8 days) (Bogner et al., 2010; Near et al., 2013; O’Gorman et al.,
328 2011; Wijtenburg et al., 2013).

329 One well-known limitation of the MEGA-PRESS technique is that the
330 acquired GABA signal is contaminated by overlapping macromolecule
331 signals. As a result, the GABA quantities measured in this study do not
332 represent pure GABA, but rather a combination of GABA + macromole-
333 cules. The results of this study therefore suggest that both GABA and
334 macromolecular levels are likely relatively stable over long periods of
335 time, thus further reinforcing the internal validity of longitudinal (inter-
336 ventional) and correlational studies of GABA levels using MEGA-PRESS.

337 Acknowledgments

338 We would like to thank the FMRI Centre, University of Oxford,
339 for providing the MEGA-PRESS sequence, and Benjamin de Haas of

University College London, for providing code to calculate likeli- 340
hood ratio distributions based on code by Professor Zoltan Dienes 341
of Sussex University ([http://www.lifesci.sussex.ac.uk/home/Zoltan_](http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/BayesFactor.html) 342
[Dienes/inference/BayesFactor.html](http://www.lifesci.sussex.ac.uk/home/Zoltan_Dienes/inference/BayesFactor.html)). 343

References 344

- Bhagwagar, Z., Wylezinska, M., Jezzard, P., Evans, J., Ashworth, F., Sule, A., Matthews, P.M., 345
Cowen, P.J., 2007. Reduction in occipital cortex gamma-aminobutyric acid concentra- 346
tions in medication-free recovered unipolar depressed and bipolar subjects. *Biol.* 347
Psychiatry 61, 806–812. 348
- Bogner, W., Gruber, S., Doelken, M., Stadlbauer, A., Ganslandt, O., Boettcher, U., Trattng, S., 349
Doerfler, A., Stefan, H., Hammen, T., 2010. In vivo quantification of intracerebral GABA 350
by single-voxel (1)H-MRS-How reproducible are the results? *Eur. J. Radiol.* 73, 351
526–531. 352
- Boy, F., Evans, C.J., Edden, R.A., Singh, K.D., Husain, M., Sumner, P., 2010. Individual differ- 353
ences in subconscious motor control predicted by GABA concentration in SMA. *Curr.* 354
Biol. 20, 1779–1785. 355
- Boy, F., Evans, C.J., Edden, R.A., Lawrence, A.D., Singh, K.D., Husain, M., Sumner, P., 2011. 356
Dorsolateral prefrontal gamma-aminobutyric acid in men predicts individual differences 357
in rash impulsivity. *Biol. Psychiatry* 70, 866–872. 358
- Cicchetti, D.V., Sparrow, S.A., 1981. Developing criteria for establishing interrater reliability 359
of specific items: applications to assessment of adaptive behavior. *Am. J. Ment. Defic.* 86, 360
127–137. 361
- Donahue, M.J., Near, J., Blicher, J.U., Jezzard, P., 2010. Baseline GABA concentration and 362
fMRI response. *NeuroImage* 53, 392–398. 363
- Edden, R.A., Crocetti, D., Zhu, H., Gilbert, D.L., Mostofsky, S.H., 2012a. Reduced GABA con- 364
centration in attention-deficit/hyperactivity disorder. *Arch. Gen. Psychiatry* 69, 365
750–753. 366
- Edden, R.A., Intrapirromkul, J., Zhu, H., Cheng, Y., Barker, P.B., 2012b. Measuring T2 in vivo 367
with J-difference editing: application to GABA at 3 Tesla. *J. Magn. Reson. Imaging* 35, 368
229–234. 369
- Epperson, C.N., Gueorguieva, R., Czarkowski, K.A., Stiklus, S., Sellers, E., Krystal, J.H., 370
Rothman, D.L., Mason, G.F., 2006. Preliminary evidence of reduced occipital GABA 371
concentrations in puerperal women: a 1H-MRS study. *Psychopharmacology (Berl)* 372
186, 425–433. 373
- Evans, C.J., McGonigle, D.J., Edden, R.A., 2010. Diurnal stability of gamma-aminobutyric 374
acid concentration in visual and sensorimotor cortex. *J. Magn. Reson. Imaging* 31, 375
204–209. 376
- Foerster, B.R., Callaghan, B.C., Petrou, M., Edden, R.A., Chenevert, T.L., Feldman, E.L., 2012. 377
Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. 378
Neurology 78, 1596–1600. 379
- Gao, F., Edden, R.A.E., Li, M., Puts, N.A.J., Wang, G., Lui, C., Zhao, B., Wang, H., Bai, X., Zhao, C. 380
, Wang, X., Barker, P.B., 2013. Edited magnetic resonance spectroscopy detects an age- 381
related decline in brain GABA levels. *NeuroImage* 78, 75–82. 382
- Harada, M., Kubo, H., Nose, A., Nishitani, H., Matsuda, T., 2011. Measurement of variation 383
in the human cerebral GABA level by in vivo MEGA-editing proton MR spectroscopy 384
using a clinical 3 T instrument and its dependence on brain region and the female 385
menstrual cycle. *Hum. Brain Mapp.* 32, 828–833. 386
- Jocham, G., Hunt, L.T., Near, J., Behrens, T.E., 2012. A mechanism for value-guided choice 387
based on the excitation–inhibition balance in prefrontal cortex. *Nat. Neurosci.* 15, 388
960–961. 389
- Kegeles, L.S., Mao, X., Stanford, A.D., Girgis, R., Ojeil, N., Xu, X., Gil, R., Slifstein, M., Abi- 390
Dargham, A., Lisanby, S.H., Shungu, D.C., 2012. Elevated prefrontal cortex gamma- 391
aminobutyric acid and glutamate–glutamine levels in schizophrenia measured 392
in vivo with proton magnetic resonance spectroscopy. *Arch. Gen. Psychiatry* 69, 393
449–459. 394
- Lei, H., Berthet, C., Hirt, L., Gruetter, R., 2009. Evolution of the neurochemical profile after 395
transient focal cerebral ischemia in the mouse brain. *J. Cereb. Blood Flow Metab.* 29, 396
811–819. 397
- McCormick, D.A., 1989. GABA as an inhibitory neurotransmitter in human cerebral cortex. 398
J. Neurophysiol. 62, 1018–1027. 399
- McGraw, K.O., Wong, S.P., 1996. Forming inferences about some intraclass correlation 400
coefficients. *Psychol. Methods* 1, 30–46. 401
- Mescher, M., Merkle, H., Kirsch, J., Garwood, M., Gruetter, R., 1998. Simultaneous in vivo 402
spectral editing and water suppression. *NMR Biomed.* 11, 266–272. 403
- Muthukumaraswamy, S.D., Edden, R.A., Jones, D.K., Swettenham, J.B., Singh, K.D., 2009. 404
Resting GABA concentration predicts peak gamma frequency and fMRI amplitude 405
in response to visual stimulation in humans. *Proc. Natl. Acad. Sci. U. S. A.* 106, 406
8356–8361. 407
- Naressi, A., Couturier, C., Devos, J.M., Janssen, M., Mangeat, C., de Beer, R., Graveron- 408
Demilly, D., 2001. Java-based graphical user interface for the MRUI quantitation package. 409
MAGMA 12, 141–152. 410
- Near, J., Simpson, R., Cowen, P., Jezzard, P., 2011. Efficient gamma-aminobutyric acid 411
editing at 3 T without macromolecule contamination: MEGA-SPECIAL. *NMR Biomed.* 412
24, 1277–1285. 413
- Near, J., Andersson, J., Maron, E., Mekle, R., Gruetter, R., Cowen, P., Jezzard, P., 2013. 414
Unedited in-vivo detection and quantification of GABA in the occipital cortex 415
using short-TE magnetic resonance spectroscopy at 3 Tesla. *NMR Biomed.* 26, 416
1353–1362. 417
- Near, J., Edden, R., Evans, C.J., Paquin, R., Harris, A., Jezzard, P., 2014. Frequency and phase 418
drift correction of magnetic resonance spectroscopy data by spectral registration in 419
the time domain. *Magn. Reson. Med.* 72

- 421 O’Gorman, R.L., Edden, R.A., Michels, L., Murdoch, J.B., Martin, E., 2011. Precision and
422 repeatability of in vivo GABA and glutamate quantification. *Proc. Int. Soc. Magn.*
423 *Reson. Med.* 19, 3440.
- 424 Petroff, O.A., Rothman, D.L., Behar, K.L., Mattson, R.H., 1996. Low brain GABA level is asso-
425 ciated with poor seizure control. *Ann. Neurol.* 40, 908–911.
- 426 Petty, F., Kramer, G.L., Fulton, M., Davis, L., Rush, A.J., 1995. Stability of plasma GABA at
427 four-year follow-up in patients with primary unipolar depression. *Biol. Psychiatry*
428 37, 806–810.
- 429 Rowland, L.M., Kontson, K., West, J., Edden, R.A., Zhu, H., Wijtenburg, S.A., Holcomb, H.H.,
430 Barker, P.B., 2013. In vivo measurements of glutamate, GABA, and NAAG in schizo-
431 phrenia. *Schizophr. Bull.* 39, 1096–1104.
- Sandberg, K., Blicher, J.U., Dong, M.Y., Rees, G., Near, J., Kanai, R., 2013. Occipital GABA cor- 432
relates with cognitive failures in daily life. *NeuroImage*. [http://dx.doi.org/10.1016/j.](http://dx.doi.org/10.1016/j.neuroimage.2013.10.059) 433
[neuroimage.2013.10.059](http://dx.doi.org/10.1016/j.neuroimage.2013.10.059). 434
- Stephenson, M.C., Gunner, F., Napolitano, A., Greenhaff, P.L., Macdonald, I.A., Saeed, N., 435
Vennart, W., Francis, S.T., Morris, P.G., 2011. Applications of multi-nuclear magnetic 436
resonance spectroscopy at 7 T. *World J. Radiol.* 3, 105–113. 437
- Sumner, P., Edden, R.A., Bompas, A., Evans, C.J., Singh, K.D., 2010. More GABA, less distrac- 438
tion: a neurochemical predictor of motor decision speed. *Nat. Neurosci.* 13, 825–827. 439
- Wijtenburg, S.A., Rowland, L.M., Edden, R.A., Barker, P.B., 2013. Reproducibility of brain 440
spectroscopy at 7 T using conventional localization and spectral editing techniques. 441
J. Magn. Reson. Imaging 38, 460–467.

UNCORRECTED PROOF